Page 5 - Sciences Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sciences group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sciences Group Today - Breaking & Trending Today

SELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Study

SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on cancer, announced Tuesday positive topline data from the Phase 2a study of SLS009 in relapsed or refractory acute myeloid leukemia or r/r AML. ....

Angelos Stergiou , Life Sciences Group Inc , Steering Committee , More Such Health News , Sciences Group , Chief Executive Officer ,

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML

SELLAS Life Sciences Group, Inc. announced topline data from the Phase 2a study of SLS009 and provides an update on Phase 3 REGAL Study of GPS in AML. The REGAL Steering Committee met on March 22,. ....

Steering Committee , Sellas Life Sciences Group Inc , Sciences Group , Topline Data , All Dose ,

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and ...

- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April- ....

Bruce Mackle , Angelos Stergiou , Steering Committee , Genfleet Therapeutics Shanghai Inc , Lifesci Advisors , Steering Committee Guided Interim Analysis Imminent , Company To Host Corporate Update Webinar , Life Sciences Group Inc , Memorial Sloan Kettering Cancer Center , Enrollment Completed , Response Rate , Selected Optimal Dose , Identified Biomarkers , Not Been Reached , Remains Leukemia Free , Strong Anti Leukemic Activity , Favorable Safety Profile , All Dose Levels , Host Corporate Update Webinar Today , Sciences Group , Chief Executive Officer , Topline Data , Genfleet Therapeutics , Annual Report , Sci Advisors ,

SELLAS Announces Positive Topline Data from the Phase 2a

- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April - - Phase. ....

Angelos Stergiou , Bruce Mackle , Steering Committee , Memorial Sloan Kettering Cancer Center , Genfleet Therapeutics Shanghai Inc , Lifesci Advisors , Company To Host Corporate Update Webinar , Life Sciences Group Inc , Steering Committee Guided Interim Analysis Imminent , Enrollment Completed , Late April , Response Rate , Selected Optimal Dose , Identified Biomarkers , Not Been Reached , Remains Leukemia Free , Strong Anti Leukemic Activity , Favorable Safety Profile , All Dose Levels , Host Corporate Update Webinar Today , Sciences Group , Chief Executive Officer , Topline Data , Genfleet Therapeutics , Annual Report , Sci Advisors ,

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the ...

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ....

United States , Bruce Mackle , Tapan Kadia , Department Of Leukemia , Memorial Sloan Kettering Cancer Center , European School Of Haematology Acute Leukaemias , Life Sciences Group Inc , Lifesci Advisors , Genfleet Therapeutics Shanghai Inc , University Of Texas Md Anderson Cancer Center , Sciences Group , Haematology Acute Leukaemias , Treat Acute Leukaemias , Friday March , Escalation Study , Acute Myeloid , Leukemia Treatment , Cancer Center , Genfleet Therapeutics , Annual Report , Sci Advisors ,